A

Amgen

Makes biotech medicines for serious illnesses

Encryption Agility Engineer

Full-TimeUpdated
No salary listed
Senior, Expert
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • A doctorate in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field, plus experience as stated for this qualification path.
  • A master's degree in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field, with 4 to 6 years of relevant experience.
  • A bachelor's degree in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field, with 6 to 8 years of relevant experience.
  • A diploma with 10 to 12 years of relevant experience in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field.
  • Strong hands-on knowledge of enterprise cryptography, including Public Key Infrastructure (PKI), X.509 certificates, Transport Layer Security (TLS), cipher suites, Key Management Services (KMS), Hardware Security Modules (HSMs), secrets management, key lifecycle, encryption at rest and in transit, cloud key services, identity protocols, and certificate lifecycle automation.
  • Practical experience with cryptographic discovery, Cryptographic Bill of Materials (CBOM)-driven inventory, source code scanning, network and endpoint telemetry, cloud key service analysis, false-positive triage, data quality controls, dashboards, and remediation tracking.
  • Working knowledge of post-quantum cryptography, crypto agility, National Institute of Standards and Technology (NIST)-approved algorithms and standards, hybrid transition patterns, Steal-Now-Decrypt-Later (SNDL) risk reduction, and risk-prioritized remediation.
  • Ability to convert cryptographic policy, architecture direction, and scan findings into actionable engineering guidance across Continuous Integration/Continuous Delivery (CI/CD), Secure Software Development Life Cycle (SSDLC), cloud platforms, PKI and certificates, KMS and secrets, identity, infrastructure, applications, third-party governance, and risk management.
  • Experience designing and implementing Artificial Intelligence (AI)-enabled process orchestration for security, cryptography, governance, risk, compliance, or technology operations workflows, including AI agents or multi-agent patterns that reduce manual effort, improve analysis consistency, increase team throughput, and maintain human-in-the-loop review for high-risk or decision-bearing activities.
  • Ability to architect AI agents to achieve defined service actions and outcomes, including workflow decomposition, agent role definition, tool and data-source integration, prompt and instruction design, validation checkpoints, exception handling, auditability, and escalation paths for human review.
  • Strong analytical, troubleshooting, and problem-solving skills.
  • Strong technical ownership and ability to drive complex discovery, analysis, and remediation work to completion.
  • Strong verbal and written communication skills for technical, business, compliance, procurement, and vendor audiences.
  • Ability to translate cryptographic findings into clear risk statements, remediation options, and implementation steps.
  • Ability to influence without direct authority across global security, Digital, Technology and Innovation (DTI), Digital Identity Access Service (DIAS), procurement, legal, compliance, Operational Technology (OT), infrastructure, cloud, and application teams.
  • High degree of initiative, accountability, judgment, and self-motivation in ambiguous or evolving technical domains.
  • Team-oriented approach focused on shared outcomes, reusable patterns, practical implementation, and service maturity.
  • Strong coaching and mentoring skills for Global Career Framework level 4 (L4) analysts and technical contributors.
  • Strong documentation, presentation, and knowledge-sharing skills for technical reviews, service updates, and architecture forums.
  • Ability to identify manual process bottlenecks, redesign workflows for automation and AI augmentation, and balance productivity improvements with quality, accountability, and human judgment.
Responsibilities
  • Execute assigned Encryption Agility Service workstreams, including intake analysis, backlog execution, roadmap tracking, service metrics, reporting inputs, Standard Operating Procedure (SOP) updates, and service improvement actions under the direction of the Senior Manager and Principal Architect.
  • Operate enterprise cryptographic discovery across source code, binaries, cloud key services, endpoints, file systems, network traffic, PKI and certificates, KMS and secrets, vendor attestations, Software Bill of Materials (SBOM) inputs, and Subject Matter Expert (SME) interviews.
  • Build, maintain, and improve the enterprise CBOM using CycloneDX 1.6 or later as the target format, including required fields, source systems, ownership attributes, quantum-vulnerability status, remediation status, data quality checks, reporting views, and asset correlation.
  • Support tool integration and data normalization across enterprise and cryptographic discovery platforms.
  • Analyze cryptographic scan outputs, source code findings, certificate chains, cipher suite configurations, TLS settings, Secure Shell (SSH) settings, Open Authorization (OAuth), Security Assertion Markup Language (SAML), JSON Web Token (JWT) patterns, cloud key configurations, and key or secret storage patterns.
  • Implement and document remediation patterns approved by the Principal Architect, including hybrid TLS, proxy-based crypto agility, network encapsulation, Internet Protocol Security (IPsec), Media Access Control Security (MACsec), Key Management Interoperability Protocol (KMIP), Public-Key Cryptography Standard #11 (PKCS#11), provider libraries, custom code libraries, symmetric cryptography, Hash-Based Message Authentication Code (HMAC), TLS termination, reverse proxies, encrypted overlays, segmentation controls, compensating controls, and risk-based replacement or decommission pathways.
  • Coordinate with DIAS, PKI service owners, certificate management teams, identity teams, cloud, infrastructure, and platform teams on certificate visibility, Certificate Lifecycle Manager (CLM) evaluation, certificate rotation, migration from manual to automated deployment, post-quantum PKI readiness, hybrid certificate testing, Certificate Authority (CA) modernization, KMS strategy, HSM patterns, secrets management, key rotation, key retirement, storage standards, ownership, reporting, and centralized or federated control options.
  • Partner with Application Security, AI Security, Enterprise Architecture, Development and Operations (DevOps), and engineering teams to publish approved cryptographic libraries, secure code examples, reusable patterns, CI/CD controls, SSDLC requirements, scanning rules, developer remediation playbooks, and practical implementation guidance.
  • Apply the approved quantum risk-prioritization approach to discovery and remediation planning for business-critical applications, high-volume sensitive data flows, third-party dependencies, identity services, legacy platforms, Key Computerized Systems (KCS), validated Good x Practice (GxP) systems, and OT scope.
  • Support vendor and third-party technical governance with Procurement, Legal, Risk and Compliance, Third Party Risk Management (TPRM), and business owners by preparing technical questionnaire content, CBOM requests, evidence reviews, roadmap tracking, contract language inputs, escalation triggers, and supplier remediation follow-up.
  • Provide technical escalation and mentoring for L4 analysts and contributors, maintain cryptographic knowledge articles and implementation guides, and track changes in NIST, Internet Engineering Task Force (IETF), National Security Agency Commercial National Security Algorithm Suite 2.0 (NSA CNSA 2.0), International Organization for Standardization (ISO), Health Insurance Portability and Accountability Act (HIPAA), Health Information Trust Alliance (HITRUST), and broader industry cryptography guidance.
  • Design, implement, and govern AI-enabled process orchestration for human-intensive Encryption Agility Service workflows, including cryptographic inventory analysis, CBOM data normalization, scan output review, evidence collection, remediation tracking, reporting, and governance workflows. Architect AI agents or coordinated teams of AI agents for data ingestion, finding correlation, false-positive triage support, ownership enrichment, remediation recommendation drafting, dashboard preparation, and knowledge article generation, while ensuring human-in-the-loop controls for risk decisions, exceptions, production changes, and final approval actions.
Desired Qualifications
  • Hands-on experience with ServiceNow Configuration Management Database (CMDB)/Governance, Risk, and Compliance (GRC), Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, GitGuardian, Amazon Web Services (AWS) KMS, AWS Certificate Manager, AWS Secrets Manager, Microsoft PKI, Sectigo, HashiCorp Vault, HSMs, CLM platforms, and Security Information and Event Management (SIEM)/data lake integrations.
  • Experience creating or operating CBOM/SBOM data models using CycloneDX 1.6 or later, Application Programming Interfaces (APIs), Comma-Separated Values (CSV), JavaScript Object Notation (JSON), dashboards, data quality checks, and audit-ready reporting.
  • Experience with PKI modernization, certificate automation, certificate rotation, CA hierarchy changes, hybrid certificate testing, and Post-Quantum Public Key Infrastructure (PQ-PKI) transition support.
  • Experience with key management and secrets management across AWS, Azure, on-premises platforms, HSMs, vault technologies, automation workflows, and centralized or federated operating models.
  • Experience with application security, DevOps, SSDLC governance, CI/CD quality gates, approved cryptographic libraries, static analysis, dynamic analysis, composition analysis, and developer enablement.
  • Experience in pharmaceutical, life sciences, regulated, validated, GxP, KCS, manufacturing, OT, or other change-controlled environments.
  • Scripting and automation experience with Python, PowerShell, Bash, REST APIs, data pipelines, parsing certificate or scan data, or lightweight integration development.
  • Certified Information Systems Security Professional (CISSP).
  • Certified Cloud Security Professional (CCSP), AWS Certified Security - Specialty, Microsoft Azure Security Engineer, or equivalent cloud security certification.
  • Certified Information Security Manager (CISM), Certified Information Systems Auditor (CISA), or Certified in Risk and Information Systems Control (CRISC).
  • Security+, Systems Security Certified Practitioner (SSCP), or equivalent security certification.
  • Relevant PKI, KMS, HSM, cryptographic discovery, certificate lifecycle management, cloud key management, or post-quantum cryptography training or certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.